Paul Kemp

Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development.

Organogenesis, Inc. designs and manufactures regenerative medical products. It offers Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers and Dermagraft, a product for the treatment of diabetic foot ulcers. The firm also provides bioactive wound healing, biosurgery, and aesthetic medicine containing living cells and natural connective tissues. The company was founded in 1985 and is headquartered in Canton, MA.

The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds.

Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom.